Session II: NASH Progression and Co-morbidities

This is an exciting session that will cover topics related to childhood NAFLD/NASH. In addition, there will be updates on NASH related HCC and liver transplantation. The utilization of NITs to risk stratify patients and predict response to therapy will also be discussed. 

SPEAKERS 

Moderators:
Rohit Loomba, MD
Naim Alkhouri, MD

Presenters:
Marialena Mouzaki, MD - Diagnosis and Management of Pediatric NASH
Naim Alkhouri, MD - How to Use NIT in Risk Stratification in Clinical Care?
Veeral H. Ajmera, MD - NASH Related HCC and Liver Transplantation
Nobuharu Tamaki, MD - Clinical Utility of 30% Relative Decline in MRI-PDFF in Predicting Fibrosis Regression in Nonalcoholic Fatty Liver Disease
Marialena Mouzaki, MD - Characteristics of Children with NAFLD and Advanced Hepatic Fibrosis
Elizabeth C. Verna, MD, MS - Impact of COVID-19 on Clinical Trial Design and Participation